Behçet disease is known to be a multisystem condition. We conducted a study to determine the prevalence of hearing loss in patients with Behçet disease and to identify any associations between audiologic findings and other clinical manifestations and treatment. Our study group was made up of 41 adults with Behçet disease and 41 healthy sex-and age-matched controls. All patients and controls underwent a complete clinical otolaryngologic examination, which included pure-tone audiometry, acoustic impedance testing, and otoacoustic emissions testing. Audiology revealed that the prevalence of sensorineural hearing loss (SNHL) was significantly higher in the Behçet patients than in the controls-68.3 vs. 22.0% (p < 0.002). The duration of Behçet disease had no significant impact on whether patients did or did not experience hearing loss. Hearing loss was the fourth most common clinical finding in the Behçet group, after oral ulcers, genital ulcers, and skin lesions. We conclude that SNHL is present in a significant number of Behçet patients, and we suggest the need for an adequate investigation of hearing in the routine follow-up of these patients.
Introduction
Behçet disease was first described in 1937 by the Turkish dermatologist Hulusi Behçet. 1 It is a complex multisystem condition that is characterized by a generalized vasculitis of the small vessels. 2 Affected patients typically present with recurrent oral and genital ulcerations, as well as ocular involvement. 1 Diagnostic criteria published by the International Study Group for Behçet's Disease require the presence of oral aphthae plus two of the following: genital aphthae, eye lesions, skin lesions, or a positive pathergy test. 3 Although its etiology is unknown, Behçet disease is considered to be an autoimmune disease with a genetic basis. 4, 5 Its prevalence is highest in southern Europe, Southeast Asia, and Japan. 6, 7 The clinical course of Behçet disease is variable, and cardiovascular, pulmonary, central nervous system, gastrointestinal system, and joint involvement has been reported. 8 According to published surveys, the prevalence of hearing impairment varies greatly, ranging from 12.5 to 80%. [9] [10] [11] [12] We conducted a study to determine the prevalence of hearing loss in patients with Behçet disease and to identify any associations between audiologic findings and other clinical manifestations and treatment. Our goal was to ascertain the importance of audiologic evaluations in the management of patients with Behçet disease.
Patients and methods
Our study group was made up of 41 patients with Behçet disease-22 men and 19 women, aged 21 to 68 years (mean: 39.3 ± 11.02)-who had been followed up in the Department of Dermatology at Zonguldak Karaelmas University. All patients met the diagnostic criteria for Behçet disease established by the International Study Group for Behçet's Disease. 3 Their duration of disease ranged from 1 to 30 years (mean: 11.25 ± 9.14). Exclusion criteria included a history of head or ear trauma, use of ototoxic drugs, the presence of an otologic or neurologic disease unrelated to Behçet disease, and any metabolic, autoimmune, or connective tissue disorder that has been associated with sensorineural hearing loss (SNHL).
For a control group, we identified an age-and sex-matched group of 41 healthy subjects without hearing impairment-21 men and 20 women, aged 19 to 63 years (mean: 40.9 ± 11.79). There were no statistically significant differences between the two groups in terms of age and sex. All eligible patients and controls underwent a complete clinical otolaryngologic examination, which included pure-tone audiometry, acoustic impedance testing, and otoacoustic emissions testing. All patients and controls had an intact tympanic membrane, and all other findings on otoscopic examination were normal.
All hearing tests were performed by experienced audiologists. Conventional pure-tone audiometry was conducted in a standard soundproof room with an AC40 clinical audiometer (Interacoustics; Assens, Denmark). The acoustic thresholds at 250, 500, 1,000, 2,000, 4,000, and 8,000 Hz were calculated for each ear.
Acoustic reflex thresholds were obtained with an Amplaid 728 impedance meter (Amplifon; Milan, Italy) in 5-dB increments up to a maximum output of 110 dB HL ipsilaterally and contralaterally.
Transient evoked otoacoustic emissions (TEOAEs) were recorded with an ILO88 analyzer (v. 292; Otodynamics; Hatfield, U.K.) with a post-stimulus analysis window of 20 ms. The repetition rate was 50 Hz, and the stimulus intensity was 83 dB. The testing was performed with the standard ILO adult foam-tip probe, and the analyses were conducted automatically by the system.
Statistical analyses were performed with the Statistical Package for the Social Sciences software (v. 11.01; SPSS; Chicago). Statistical evaluations were carried out with (1) the independent-samples t test for comparison of measurements of groups for parametric conditions, (2) the Mann-Whitney U test for nonparametric conditions, and (3) the chi-square test for relationships between two categorical variables. A p value of <0.05 was considered significant.
The study protocol was approved by the Ethics Committee of the Zonguldak Karaelmas University School of Medicine.
Results
Audiologic findings. The results of pure-tone audiometry showed that patients with Behçet disease had a higher prevalence of SNHL (>20 dB at least in one of the tested frequencies) than did the controls (table 1) . SNHL was present in 28 patients with Behçet disease (68.3%), compared with only 9 controls (22.0%); the difference was statistically significant (p < 0.002). Some 21 Behçet patients had bilateral SNHL and 7 had a unilateral loss. The rate of SNHL was significantly higher (p < 0.05) in the men with Behçet disease (19/22; 86.4%) than in the women (9/19; 47.4%). The typical audiometric configuration was a downward sloping in the high frequencies.
Acoustic reflex measurements were within normal limits in all patients and controls. Upper limits that did not exceed 105 dB HL were considered normal.
TEOAE responses were significantly different in the two groups. The TEOAE reproducibility and amplitude values of the Behçet patients were significantly lower than those of the controls (p < 0.0001).
Duration of disease. Among the Behçet patients, no statistically significant difference was seen in the duration of disease between those with and without hearing loss (table 2) .
Associations with other factors. Oral ulcers were noted in all 41 Behçet patients, and genital ulcers were found in 34 (82.9%) (table 3) . Skin lesions were present in 31 patients (75.6%), some of whom had more than one; these included 21 cases of papulopustular lesions, 16 cases of erythema nodosum, and 3 cases of superficial thrombophlebitis. None of these clinical manifestations was significantly associated with hearing loss.
A total of 31 patients had a positive pathergy test Nineteen of our Behçet patients were under colchicine treatment. We found no significant difference in the prevalence of SNHL between those who were treated with colchicine and the 22 patients who were not.
Discussion
Although the etiology and pathogenesis of Behçet disease remain unclear, vasculitis is the main pathologic process. The presence of circulating autoantibodies to human oral mucous membrane antigens, which is detected in half of Behçet patients, suggests that it is an autoimmune disease. 13 On the other hand, other factors such as infection and coagulation abnormalities may trigger T-cell production of cytokines, resulting in neutrophil activation and endothelial injury with vasculitis. 2, 14 In a histopathologic study of temporal bones from 8 persons with systemic vasculitic disorders such as Wegener granulomatosis, systemic lupus erythematosus, and polyarteritis nodosa, Yoon et al found that the subjects with systemic lupus erythematosus had significant inner ear changes. 15 In another histopathologic study of temporal bones obtained from persons who had had systemic lupus erythematosus, Sone et al found different histopathologic alterations in the inner ear, such as a loss of hair cells, atrophy of the stria vascularis, and spiral ganglion damage. 16 Since Behçet disease is considered to be a systemic autoimmune and vasculitic disease, a finding of damage to the auditory apparatus is to be expected.
Since the first description of hearing loss in Behçet disease by Alajouanine et al 17 in 1961, others 11, [18] [19] [20] have reported prevalence rates as high as 80%. Also, vestibular involvement has been reported in 10 to 59% of cases. 9, [21] [22] [23] Gemignani et al found cochlear hearing impairment in 12 of 20 patients with Behçet disease, and they concluded that the cochlea is involved more frequently than is the vestibular labyrinth. 24 As another indicator of the inner ear involvement, we found no case of sudden hearing loss in our series. However, both Berrettini et al 25 and Hagiwara et al 26 reported cases of sudden hearing loss that completely resolved after treatment with steroids and immunosuppressive agents. These findings support the hypothesis that an immunologic and vasculitic process occurs in the inner ear of patients with Behçet disease.
Behçet disease has also manifested with external ear involvement. Miura et al reported the case of a child with Behçet disease who presented with necrosis of the external ear canal, facial paresis, Horner syndrome, and rupture of the internal carotid artery. 27 In our series, SNHL was present in 28 of the 41 Behçet patients (68.3%) on pure-tone audiometry. The sloping type of audiogram (a high-frequency hearing loss with a downward slope) with bilateral SNHL that we found has also been reported by others. 19, 20 The high prevalence of hearing loss in our patients supports the need for audiologic evaluation following the definitive diagnosis. Our study was prompted by the lack of published data in dermatology literature on the importance and frequency of hearing loss in Behçet patients.
In a study of 20 patients with Behçet dis- ease, Muluk and Birol reported that males experienced greater increases in hearing thresholds and greater reductions in otoacoustic emissions than did females. 28 In our study, the prevalence of SNHL in the Behçet group was significantly higher in men than in women-86.4 vs. 47.4% (p < 0.05).
Considering a positive pathergy test as a finding rather than an associated condition, our study revealed that hearing loss was the fourth most common clinical symptom, following oral and genital ulcers and skin lesions. Our finding in this regard is consistent with some other reports, although some authors have found that SNHL was the third most common clinical manifestation. 19, [29] [30] [31] We found no statistically significant association between hearing loss and other system involvements or with a positive pathergy test. This lack of association may be attributable to the multifocal nature of the Behçet disease process. Moreover, the duration of disease in our study was not significantly different between the Behçet patients with and without hearing loss. Similarly, Soylu et al 18 and Erdinç et al 29 found no association between hearing loss and duration of disease.
As for treatment, colchicine use had no effect on the prevalence of SNHL in our Behçet group. Some controversial reports have been published on the effect of cyclosporine A treatment on hearing loss. For example, Elidan et al 11 found that it resulted in significant hearing improvement, while Soylu et al 18 observed no improvement.
Otoacoustic emissions are sounds that can be detected in the external auditory canal in almost all normal ears. It is generally accepted that they occur following an auditory stimulus. They can be viewed as representing a reverse transduction process in which rarefactions of fluid in the inner ear are transmitted to the tympanic membrane through the middle ear. Two means of assessing outer hair-cell activity are measurements of TEOAEs and distortion-product otoacoustic emissions (DPOAEs). The presence of such emissions provides, in part, evidence of the functional integrity of the entire middle ear and cochlear systems. In the very limited amount of literature available on otoacoustic findings in Behçet disease, otoacoustic emissions were found to be significantly different between affected patients and controls.
In a study conducted to investigate cochlear status in Behçet patients based on DPOAEs testing results, Dagli et al concluded that the damaged part of the cochlea is the outer hair cells. 20 On the other hand, Muluk and Birol found that TEAOE values were significantly lower in patients with Behçet disease. 28 They also reported that as age increased, hearing thresholds increased and TEOAEs decreased. Similar to these findings, which reflect the inner ear's involvement in Behçet disease, we found that the TEOAE responses of our Behçet patients were significantly lower than those of the controls (p < 0.0001) and that the decreased TEOAEs were seen in Behçet patients who had increased hearing thresholds.
Finally, Behçet disease frequently presents with dermatologic symptoms, and therefore patients are often first evaluated by a dermatologist. Because SNHL occurs in a significant proportion of cases, an adequate investigation of hearing is important during the routine follow-up of patients with Behçet disease.
